Cellix Customers
Since the company was established in 2006, Cellix's unique platform has attracted attention from the academic community and top pharma and biotech companies worldwide. Today, the Cellix solution is used by over a third of the top ten ranking pharmaceutical companies.
The Cellix team work closely with customers at the consultation stage to ensure the best fit of the platform within their specialist disease area. Part of this is a no obligation trial within the customers' own lab to demonstrate the benefits the solution can bring to their drug screening process.
Companies currently using the Cellix solution within their drug discovery programme include:
- AstraZeneca (Sweden)
- BioTie Therapies (Finland)
- National Institute of Health (US)
- Pfizer (US)
- Sanofi-Aventis (Germany)
- Servier (France)
- Yale University (US)
- Univeristy of Reading (UK)
- University of Liverpool (UK)
- University of Washington (US)
Within these organisations, the main use of the Cellix solution is to study cell adhesion, migration and shear stress models across disease areas such as cardiovascular, immunology, oncology, respiratory and bacteriology.
Click here to see full range of validated therapeutic areas for the Cellix solution.